- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Lantern Pharma Projected to Post Q4 2025 Earnings
The clinical-stage oncology company will likely announce results before the market opens on Thursday, March 26th.
Mar. 25, 2026 at 5:36am
Got story updates? Submit your updates here. ›
Lantern Pharma (NASDAQ:LTRN), a clinical-stage oncology company leveraging artificial intelligence and machine learning, is expected to report its Q4 2025 financial results before the market opens on Thursday, March 26th. Analysts estimate the company will announce earnings of ($0.46) per share for the quarter.
Why it matters
Lantern Pharma's upcoming earnings report will provide insight into the company's financial performance and progress in developing its pipeline of targeted cancer therapies using its proprietary RADR® platform. As a clinical-stage biotech, Lantern's earnings are closely watched by investors interested in the company's ability to advance its drug candidates.
The details
Lantern Pharma stock opened at $2.23 on Wednesday. The company has a 50-day moving average of $2.84 and a 200-day moving average of $3.43. Lantern Pharma has a 52-week low of $2.03 and a 52-week high of $5.74, with a market capitalization of $24.93 million.
- Lantern Pharma will likely report its Q4 2025 results before the market opens on Thursday, March 26th.
- The company has scheduled an earnings call for Monday, March 30, 2026 at 4:30 PM ET.
The players
Lantern Pharma
A clinical-stage oncology company leveraging artificial intelligence and machine learning to accelerate the discovery and development of targeted cancer therapies. The company is headquartered in Dallas, Texas.
What’s next
Investors will be watching Lantern Pharma's upcoming earnings report and call for updates on the company's pipeline and financial performance.
The takeaway
As a clinical-stage biotech focused on developing innovative cancer treatments, Lantern Pharma's upcoming earnings report will be an important milestone for the company as it continues to advance its pipeline using its proprietary AI and machine learning platform.
